Navigation Links
Cell Therapeutics Announces FDA's Oncologic Drugs Advisory Committee to Review Pixantrone for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma, February 10, 2010
Date:12/16/2009

se II inhibitor with an aza-anthracenedione molecular structure that differentiates it from the anthracyclines and other related chemotherapy agents. Anthracyclines are the cornerstone therapeutic for the treatment of lymphoma, leukemia, and breast cancer. Although they are sufficiently effective to be used as first-line (initial) treatment, they cause cumulative heart damage that may result in congestive heart failure many years later. As a result, there is a lifetime limit of anthracycline doses and most patients who previously have been treated with an anthracycline are not able to receive further anthracycline treatment if their disease returns. It also can be administered through a peripheral vein rather than a central implanted catheter as required for other drugs in this class.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of the securities of CTI. Specifically, the risks and uncertainties that could affect the development of
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... TORONTO , May 22 2015 /CNW/ - The Taskforce ... are very appreciative of all the hard work that the ... the past six months. This program recognizes the needs of ... receive at least $75,000 a year, tax free, with annual ... will be eligible for annual payments of $100,000 based on ...
(Date:5/22/2015)... YORK , 22 de mayo de ... DPRX ), una compañía farmacéutica de ... comercialización de Locilex® (pexiganan cream 0.8%), y ... una presentación de póster destacando el diseño ... 3 de la Compañía que evalúan Locilex®, ...
(Date:5/22/2015)... N.C. , May 22, 2015  Effective ... to pharmaceutical brand recognition and success. ... conducted a study to provide pharmaceutical and biotech ... investment (FTEs and budget) that are being channeled ... and biotech marketing managers can utilize this report ...
Breaking Medicine Technology:Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6Effective Marketing Services Group Critical for Pharmaceutical Brand Recognition 2
... , BOSTON, Nov. 23 AMICAS, Inc. ... management solutions, today announced that it will highlight its enterprise ... America (RSNA) annual meeting from November 29 to December 4 ... in booth #7124. , (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ) ...
... , MINNEAPOLIS, Nov. 23 BridgePoint Medical announced ... for its coronary and peripheral Chronic Total Occlusion (CTO) ... and the Stingray® CTO Re-Entry System. The BridgePoint ... designed to navigate highly diseased arteries in preparation for ...
Cached Medicine Technology:AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 2AMICAS' Enterprise Imaging Solutions Highlighted at RSNA 2009 3BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries 2BridgePoint Medical(R) Receives European CE Mark for Stingray(R) and CrossBoss(TM) for Opening Completely Blocked Arteries 3
(Date:5/25/2015)... Iowa (PRWEB) May 25, 2015 ... Excellence awards for design of the wastewater ... City, Iowa.    The project received a National Recognition Award from ... Honor Award from ACEC – Iowa. Competitions held ... achievements. , The $50.2 million expansion is Iowa City’s ...
(Date:5/25/2015)... (PRWEB) May 25, 2015 ProDrop Light Show ... own VJ neon light backdrops with a click of a mouse. ... and much more all within Final Cut Pro X. , ProDrop ... such as drop zones, kaleidoscope and much more leaving infinite possibilities ... Show drop zones and text presets, users can apply their ...
(Date:5/25/2015)... (PRWEB) May 25, 2015 After the ... the radical science-based human wellness company Trivedi Master ... event from their world-class series titled, “Consciousness is Power.” ... on June 13, 2015 at the routinely allotted time ... The event will be made available to the public ...
(Date:5/25/2015)... White Plains, NY (PRWEB) May 25, 2015 ... LEED AP, principal of PBDW Architects in New York City, ... which is part of the hospital’s ongoing Legacy Lobby Lecture ... campus in White Plains. White is the great grandson of ... firm responsible for the design of Burke’s campus 100 years ...
(Date:5/24/2015)... Kong (PRWEB) May 25, 2015 Pacific Prime has ... three part report looking at the cost of individual international ... Destinations, Article 2 looks at the cost of health insurance in ... , Focusing on, Hong Kong , ... the UAE , the UK ...
Breaking Medicine News(10 mins):Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 2Health News:Stanley Consultants’ Expansion of Iowa City Wastewater Treatment Plant Wins National Award 3Health News:Developers at Pixel Film Studios Release of ProDrop Light Show for Final Cut Pro X. 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 2Health News:Hundreds of People Are Thrilled to Hear that Trivedi Master Wellness™ Promises to Hold Another Workshop in June 2015 3Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 2Health News:Burke Rehabilitation Hospital Welcomes Architect Samuel White, Descendant of McKim, Mead and White, for Legacy Lobby Lecture 3Health News:Pacific Prime Releases 2nd Article of Cost of Health Insurance Report 2
... study of sexual risk behaviors within long-term couples in ... much risk in their sexual behavior when they know ... as when they know their partner is already infected. ... antiretroviral therapy and in intensive counseling do engage in ...
... Boston University School of Medicine (BUSM) have discovered that ... have the propensity to become autoantigens. In a companion ... with dead cells and that the resulting DSautoantigen complexes ... in-vitro and in mouse models. These findings, which appear ...
... Slone Epidemiology Center, in collaboration with the Centers for ... Public Health, have reported widespread and increasing medication use ... in the American Journal of Obstetrics and Gynecology ... status, maternal age, race/ethnicity and state of residence. ...
... PA April 22, 2011 - Sanofi Pasteur, the ... NYSE: SNY), announced today that the U.S. Food and ... indication for its meningococcal conjugate vaccine, Menactra (Meningococcal [Groups ... Vaccine), to include a two-dose schedule for infants and ...
... (HealthDay News) -- While it may be true that beauty ... model helps reveal what,s behind peoples, ideas of facial attractiveness. ... "average" faces and those who fit the conventional notion of ... "femininity" in women. But psychologists Christopher P. Said of New ...
... American Society of Pediatric Otolaryngology (ASPO) will hold its ... 2011 Combined Otolaryngology Spring Meetings (COSM) - a joint ... During the ASPO meeting, hundreds of pieces of new ... will be presented focusing on children,s ear, nose, and ...
Cached Medicine News:Health News:Fighting HIV in South Africa should focus on couples, study finds 2Health News:Fighting HIV in South Africa should focus on couples, study finds 3Health News:Researchers identify novel pathophysiologic mechanism responsible for autoimmunity 2Health News:Researchers report widespread use of medications among pregnant women 2Health News:Sanofi Pasteur announces FDA approval of menactra meningococcal conjugate vaccine indication for infants 2Health News:What Makes a Face Appealing to the Opposite Sex? 2Health News:Scientific session and new research highlights from the American Society of Pediatric Otolaryngology Meeting 2
... Flowstar is a compact and digital ... The investigation starts automatically when the ... volume scales can be adjusted and ... user selectable. Siroky flow plots can ...
UroPass Open Tip Ureteral Stents perfect over-the-wire placement with a combination of flexibility and rigidity for comfort and control. When it comes to stent designs, UroPass is a proven leader....
... ACMI™ Uro-Guide Open ... the first silicone over-the-wire ... classic Double-J design with ... are composed of time-tested ...
... Open Tip Ureteral Stents combine a unique ... while remembering its shape with a chemically ... moistened. The result is a stent that ... and patient comfort. Lubri-Flex® is available in ...
Medicine Products: